Industry news that matters to you.  Learn more

Archives for December 2012

UK Team Inhibits Alzheimer’s Biomarkers in Animal Model by Targeting Astrocytes

A research team composed of University of Kentucky researchers has published a paper which provides the first direct evidence that activated astrocytes could play a harmful role in Alzheimer’s disease. The UK Sanders-Brown Center on Aging has also received significant new National Institutes of Health (NIH) funding to further this line of study.

Inform Genomics Transplant Product Shown to Predict Oral Mucositis with a High Degree of Accuracy in Patients Undergoing Conditioning Regimens Prior to Hematopoetic Stem Cell Transplant

Inform Genomics, Inc., a private company focused on developing novel platforms of genomic-based personalized medicine products for cancer supportive care, presented results that demonstrate the ability of its Transplant Product to predict a patient’s risk for developing oral mucositis (OM) prior to high dose chemotherapy as part of conditioning regimens for stem cell transplant in patients with hematologic malignancies.

Combination of Imaging Exams Improves Alzheimer’s Diagnosis

A combination of diagnostic tests, including imaging and cerebrospinal fluid biomarkers can improve prediction of conversion from mild cognitive impairment (MCI) to Alzheimer’s disease, according to a new study published online in the journal Radiology.

NeuroQuest Close to Validation Trial for Biomarker Platform in Diagnosis of Alzheimer’s

NeuroQuest, a company of the Trendlines Group’s Misgav Venture Accelerator is moving quickly towards an important validation trial for novel blood-based immune biomarkers for the diagnosis of Alzheimer’s disease. The company’s biomarker platform for neurodegenerative diseases is based on the research of Prof. Michal Schwartz , Chair of Neuroimmunology at the Weizmann Institute of Science who pioneered the concept of Protective AutoImmunity. The trial is a follow-up to the preliminary human trial performed at Sheba, Rambam, and Abarbanel Medical Centers in Israel and Methodist Neurological Institute in Houston, Texas which demonstrated up to 85% diagnostic accuracy and specificity in AD and ALS patients in mild to moderate stages versus healthy controls. The success of the validation trial would present a new approach for a simple, inexpensive, and early diagnosis of Alzheimer’s disease. Successful results may lead to new therapeutic targets for this disease, opening new directions to an industry searching for novel approaches to combat AD, given the recent failures of several Phase III trials for therapeutics targeting Beta-Amyloid reduction.

Bristol-Myers Squibb Joins Multiple Myeloma Research Foundation (MMRF) to Advance Personalized Medicine Approaches for Multiple Myeloma

The Multiple Myeloma Research Foundation (MMRF) recently announced that Bristol-Myers Squibb has joined the MMRF pre-competitive consortium (PCC) to discover and accelerate new approaches to treating multiple myeloma through the organization’s Personalized Medicine Initiative (PMI).